Liraglutide
Also known as: Victoza, Saxenda, NN2211
5 notable studies · 6 references
TLDR
Liraglutide is a once-daily GLP-1 receptor agonist with extensive human evidence for glycemic control, clinically meaningful weight reduction, and reduced major cardiovascular events in high-risk adults with type 2 diabetes, and it helped establish the clinical foundation on which newer long-acting incretin therapies were developed.
Research Supports
- Established for glycemic control in type 2 diabetes
- Established for clinically meaningful weight reduction in obesity
- Studied for reducing major cardiovascular events in high-risk type 2 diabetes
- Investigated for central appetite and satiety signaling rather than simply slowed gastric emptying
- Studied in adolescent and childhood obesity populations
Observations Reported in Research
- SCALE Obesity and Prediabetes (2015, n=3,731): −8.4 kg at 56 weeks vs. −2.8 kg with placebo
- LEADER (2016, n=9,340): major cardiovascular events in 13.0% vs. 14.9% with placebo (HR 0.87)
- Mechanistic study found ~16% reduced ad-libitum energy intake with no significant change in total 5-hour gastric emptying
- LEAD-2 (2009): liraglutide 1.8 mg reduced HbA1c ~1 point with weight loss, versus weight gain with glimepiride
- Adolescent trial (2020, n=251): greater BMI SDS reduction than placebo, with BMI rising again after discontinuation
These are brief summaries of what the referenced research examined or reported — not conclusions about safety or effectiveness, and not medical advice. See Notable Studies and Sources & References below for the full context and citations.
At a Glance
Classification: Long-acting acylated glucagon-like peptide-1 receptor (GLP-1R) agonist; GLP-1 analogue
Liraglutide is a modified analogue of human GLP-1 designed to provide much longer activity than the native hormone. It primarily activates one receptor: Liraglutide → GLP-1 That makes it useful for understanding the evolution of this drug class: Liraglutide → daily GLP-1 agonist Semaglutide → longer-acting weekly GLP-1 agonist Tirzepatide → GIP + GLP-1 Mazdutide / Survodutide → GLP-1 + glucagon Retatrutide → GIP + GLP-1 + glucagon Liraglutide has demonstrated clinically meaningful effects on glucose regulation, appetite, body weight, and cardiovascular outcomes. In the large SCALE obesity trial, liraglutide 3.0 mg produced an average 8.4-kg weight reduction after 56 weeks, versus 2.8 kg with placebo. And in LEADER, involving 9,340 adults with type 2 diabetes and high cardiovascular risk, liraglutide significantly reduced major cardiovascular events and cardiovascular death.
What Is Liraglutide?
Liraglutide is a synthetic analogue of human GLP-1. Native GLP-1 is an intestinal incretin hormone released following nutrient intake, but it is rapidly degraded and therefore has a very short circulating lifetime. Liraglutide was engineered to overcome that limitation. Its structure retains close similarity to human GLP-1 but incorporates a fatty-acid side chain that promotes reversible albumin binding. This slows absorption and clearance and protects the molecule from rapid degradation. Its pharmacokinetics allow once-daily, rather than meal-by-meal, administration. This represented an important stage in incretin-drug development. Semaglutide subsequently extended the same broad concept sufficiently to support once-weekly administration.
What Are Researchers Studying?
Type 2 diabetes
Type 2 diabetes was the original major clinical application for liraglutide. The six-study Phase 3 LEAD program involved more than 4,400 participants with type 2 diabetes, approximately 2,700 of whom received liraglutide. Across the program, liraglutide improved HbA1c while generally reducing body weight and carrying relatively low intrinsic hypoglycemia risk when not combined with therapies that themselves cause hypoglycemia. For example, LEAD-2 found HbA1c reductions of approximately 1 percentage point with liraglutide 1.8 mg, while body weight decreased by 1.8–2.8 kg across liraglutide groups.
Obesity and body-weight regulation
Liraglutide subsequently became an important obesity treatment at a higher 3.0-mg daily dose. The pivotal SCALE Obesity and Prediabetes trial included 3,731 adults without type 2 diabetes. At 56 weeks: Liraglutide: −8.4 kg average Placebo: −2.8 kg average At least 5% weight reduction occurred in: Liraglutide: 63.2% Placebo: 27.1% At least 10% weight reduction occurred in: Liraglutide: 33.1% Placebo: 10.6%. These numbers are substantially smaller than those observed in trials of semaglutide 2.4 mg or tirzepatide, but liraglutide was an important proof that sustained GLP-1 receptor agonism could produce clinically significant obesity treatment effects.
Appetite and energy intake
Liraglutide's weight effects appear to arise primarily through reduced appetite and energy intake, rather than increased energy expenditure. In a controlled mechanistic study of 49 adults with obesity without diabetes, liraglutide increased reported satiety and fullness, reduced hunger, and decreased ad-libitum energy intake by approximately 16%. Total five-hour gastric emptying was not significantly different from placebo, although gastric emptying during the first hour was slower with liraglutide 3.0 mg. This is an important Aminodex distinction: Liraglutide does not produce weight loss simply because it “slows digestion.” Central appetite and satiation signaling appears particularly important.
Cardiovascular outcomes
The LEADER trial transformed liraglutide from a glucose-lowering drug with favorable cardiovascular markers into one with direct randomized cardiovascular-outcome evidence. Researchers randomized 9,340 people with type 2 diabetes and high cardiovascular risk. Over a median 3.8 years, cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke occurred in: Liraglutide: 13.0% Placebo: 14.9% Hazard ratio: 0.87 Cardiovascular death occurred in 4.7% versus 6.0%, respectively. That distinction matters: reductions in weight, HbA1c, or blood pressure are risk-factor changes. LEADER measured actual cardiovascular events.
Kidney outcomes
LEADER also generated evidence suggesting kidney benefit. The composite renal outcome occurred less frequently with liraglutide, with a hazard ratio of approximately 0.78. However, much of that difference was driven by a lower incidence of new persistent macroalbuminuria, rather than dramatic reductions across every hard kidney endpoint. That makes liraglutide's renal evidence meaningfully different from newer dedicated kidney-outcomes trials such as FLOW with semaglutide. Aminodex should not flatten those evidence levels into the same claim.
Adolescent obesity
Liraglutide has also been evaluated in adolescents with obesity. A randomized trial enrolled 251 adolescents aged 12 to under 18 years who had responded poorly to lifestyle intervention alone. At 56 weeks, liraglutide produced a significantly greater reduction in BMI standard-deviation score than placebo. At least 5% BMI reduction occurred in approximately: Liraglutide: 43.3% Placebo: 18.7% and at least 10% BMI reduction occurred in 26.1% versus 8.1%. After treatment stopped, BMI increased more in the former liraglutide group—another reminder that obesity pharmacotherapy does not necessarily produce permanent biological changes after withdrawal.
Childhood obesity
Liraglutide has also been investigated in children younger than 12. The SCALE Kids trial evaluated children 6 to under 12 years old with obesity and was published in 2025. This expands the scientific evidence for GLP-1 pharmacology into younger pediatric populations, although evidence in children should remain clearly separated from adult and adolescent research.
How Does It Work?
Liraglutide activates the GLP-1 receptor. Pancreas When glucose concentrations are elevated, GLP-1R activation increases insulin secretion. It also suppresses inappropriate glucagon secretion. These effects help reduce both fasting and postprandial glucose. Brain GLP-1-sensitive neural pathways influence: • Hunger • Satiation • Satiety • Food reward • Meal size • Overall energy intake These central effects are major contributors to liraglutide-associated weight reduction. Gastrointestinal system Liraglutide can affect gastric emptying, particularly during the earlier portion of a meal. However, controlled research found that overall five-hour gastric emptying was similar to placebo while energy intake and appetite remained substantially reduced. So: “GLP-1 drugs cause weight loss by slowing the stomach” is an oversimplification. Cardiovascular biology GLP-1 receptor agonism influences numerous cardiovascular and metabolic variables. But mechanistic plausibility is not the strongest evidence here: LEADER directly demonstrated fewer major cardiovascular events in its studied high-risk type 2 diabetes population.
What Does the Research Show?
Human research
Liraglutide has an extensive human evidence base. It includes: • Large Phase 3 diabetes programs • Large obesity trials • Active-comparator diabetes trials • Cardiovascular-outcomes research • Renal analyses • Mechanistic appetite studies • Adolescent obesity trials • Childhood obesity trials • Long-term follow-up That places liraglutide firmly on the established clinical evidence side of Aminodex. Its efficacy should therefore not be discussed in the tentative language appropriate for compounds such as BPC-157 or MOTS-c. The more useful comparison is generational. Liraglutide established many of the clinical effects that newer incretin drugs subsequently amplified.
Animal research
Preclinical liraglutide research examined: • GLP-1 receptor signaling • Glucose regulation • Insulin secretion • Food intake • Body weight • Neural appetite pathways • Pancreatic biology • Cardiovascular physiology These experiments contributed substantially to mechanistic understanding. But because large randomized human trials now exist, animal studies should play a supporting mechanistic role rather than define Aminodex's assessment of liraglutide efficacy.
In-vitro research
Cellular studies have characterized: • GLP-1 receptor activation • cAMP signaling • insulin secretion • receptor internalization • albumin binding • peptide stability • interactions with DPP-4 degradation This work helps explain why liraglutide remains active much longer than endogenous GLP-1. It also provides useful context for understanding how later GLP-1 analogues were engineered for still longer exposure.
Notable Studies
Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes: The LEAD-2 Study
humanAdults with type 2 diabetes receiving metformin were randomized to liraglutide, glimepiride, or placebo. Liraglutide 1.8 mg and glimepiride both reduced HbA1c by approximately 1.0 percentage point, but body weight decreased with liraglutide and increased with glimepiride. Minor hypoglycemia occurred in approximately 3% of liraglutide-treated participants compared with 17% receiving glimepiride.
Limitations: The study focused on glycemic efficacy rather than cardiovascular or long-term disease outcomes. Treatment lasted 26 weeks.
View publication →A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
humanResearchers randomized 3,731 adults with obesity or overweight plus weight-related complications, without diabetes, to liraglutide 3.0 mg or placebo. After 56 weeks, average weight loss was 8.4 kg with liraglutide versus 2.8 kg with placebo. At least 5% weight reduction occurred in 63.2% versus 27.1%, while at least 10% occurred in 33.1% versus 10.6%.
Limitations: The trial did not establish cardiovascular-event reduction. Participants with type 2 diabetes were excluded, and treatment was combined with lifestyle intervention.
View publication →Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
humanLEADER randomized 9,340 adults with type 2 diabetes and high cardiovascular risk to liraglutide or placebo. Median follow-up was 3.8 years. Major cardiovascular events occurred in: Liraglutide: 13.0% Placebo: 14.9% with a hazard ratio of 0.87. Cardiovascular death occurred in 4.7% versus 6.0%, and all-cause death in 8.2% versus 9.6%.
Limitations: Participants had type 2 diabetes and predominantly high cardiovascular risk. The findings should not automatically be generalized to people without diabetes or without comparable cardiovascular risk.
View publication →Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial
humanResearchers studied liraglutide 3.0 mg and 1.8 mg versus placebo for weight management in adults with overweight or obesity and type 2 diabetes. Both liraglutide doses produced greater weight reduction than placebo, with the 3.0-mg dose producing the larger effect.
Limitations: The trial lasted 56 weeks and did not assess cardiovascular events. Weight reduction in people with type 2 diabetes was smaller than that observed in the SCALE trial involving adults without diabetes.
View publication →A Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity
humanResearchers randomized 251 adolescents aged 12 to under 18 years with obesity and an inadequate response to lifestyle therapy. Liraglutide produced significantly greater improvement in BMI standard-deviation score than placebo. At least 5% BMI reduction occurred in an estimated 43.3% of liraglutide participants versus 18.7% receiving placebo.
Limitations: Treatment lasted 56 weeks, followed by 26 weeks of observation. BMI increased after discontinuation, and gastrointestinal adverse events were considerably more common with liraglutide.
View publication →What We Still Don't Know
Despite its mature evidence base, useful research questions remain: • Effects of decades-long GLP-1 receptor agonism • Optimal duration of obesity treatment • Best strategies for maintaining weight after discontinuation • Which patients respond unusually strongly or weakly • Long-term changes in lean versus fat mass • Which cardiovascular effects are mediated by weight loss, glycemic improvement, or other GLP-1 pathways • Whether there are meaningful populations in which daily liraglutide offers advantages over longer-acting agents • How its cardiovascular effects compare directly with semaglutide and newer multi-agonists • How much efficacy is gained specifically from longer receptor exposure with newer GLP-1 drugs One particularly useful lesson from liraglutide is that newer doesn't make older evidence irrelevant. Its cardiovascular-outcomes trial remains unusually valuable because it measured hard clinical events over years rather than simply changes in body weight or biomarkers.
Related Compounds
Recent publications
Latest titles from PubMed, not reviewed by Aminodex. Not an endorsement. See all on PubMed ↗
Take the Liraglutide research with you.
Get the Aminodex Liraglutide Brief—a concise summary of the research, notable studies, evidence types, limitations, and references.
One-time email. We do not add you to any mailing list.
Sources & References
- Nauck M, Frid A, Hermansen K, et al. Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes: The LEAD-2 Study. Diabetes Care. 2009.
- Pi-Sunyer X, Astrup A, Fujioka K, et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine. 2015;373:11–22. doi:10.1056/NEJMoa1411892.
- Davies MJ, Bergenstal R, Bode B, et al. Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial. JAMA. 2015;314:687–699. doi:10.1001/jama.2015.9676.
- Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. New England Journal of Medicine. 2016;375:311–322. doi:10.1056/NEJMoa1603827.
- Kelly AS, Auerbach P, Barrientos-Perez M, et al. A Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity. New England Journal of Medicine. 2020;382:2117–2128. doi:10.1056/NEJMoa1916038.
- van Can J, Sloth B, Jensen CB, Flint A, Blaak EE, Saris WHM. Effects of the Once-Daily GLP-1 Analog Liraglutide on Gastric Emptying, Glycemic Parameters, Appetite and Energy Metabolism in Obese, Non-Diabetic Adults. International Journal of Obesity. 2014;38:784–793.
Supplier Listings
A directory of relevant research suppliers for this compound is not yet available.